

Efficiency in Rewarding Pharmaceutical Innovation in the EU

Topic Manager: Anja Dekanski

How can pharmaceutical companies best be compensated for incremental therapeutic benefits of innovation? The development of innovative new therapies is a lengthy, expensive, and risky process. The challenge is balancing the pressure of maintaining government and private budgets low while adequately rewarding innovation for medications.

The goal is to stimulate innovative research and development in the pharmaceutical sector while preserving patient access. Currently, the EU has no guidelines for Member States on efficient systems of rewarding pharmaceutical innovation.

Participants of this working group will be introduced to the current working of the European Commission on this topic, as well as already existing systems of rewarding. The value of the working group will be that it combines the knowledge accumulated in the existing literature with novel and creative approaches to the topic.

The discussion will be directly relevant to the current discussion in Brussels on the topic.

Participants will be asked to collaborate and to come up with a recommendation concerning one or more aspects of rewarding pharmaceutical innovation on an EU level.